Another Lurasidone Setback As Takeda Exits Alliance
This article was originally published in The Pink Sheet Daily
Takeda has ended an alliance with fellow Japanese firm Sumitomo Dainippon for Latuda (lurasidone), dealing the second major blow to the atypical antipsychotic in recent weeks.
You may also be interested in...
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.